Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Tris Pharma Announces Approval of First-Ever Generic of Tussionex Extended-Release Suspension

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the US Food and Drug Administration (FDA) has approved first-ever generic of TUSSIONEX, an Extended-Release Suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

Tussionex was approved in the 1980's based on 1970's technology involving organic solvent based coatings. Based on its highly versatile, patent-pending technology, OralXR+™, Tris' products avoid use of toxic organic solvents by employing an aqueous based coating system. Tris pioneered the delivery of taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are traditionally associated with immediate release.

"This approval, on the back of our 2009 NDA approval for the first ever 24-hour controlled release liquid product, extends Tris' strong track record," said Ketan Mehta, President & CEO of Tris Pharma. "Tris' R&D team and engineers have not only developed a number of innovative products but also created a large, scalable manufacturing infrastructure with ample capacity to supply generic Tussionex along with our branded portfolio."

Par Pharmaceutical has begun the shipment of the Tris product under an exclusive distribution agreement. Annual U.S. sales of Tussionex® are approximately $226 million, according to IMS Health data.
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report